search
Back to results

To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma

Primary Purpose

Nasopharyngeal Carcinoma

Status
Unknown status
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
Danggui Buxue Tang
Placebo
Sponsored by
China Medical University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nasopharyngeal Carcinoma focused on measuring Nasopharyngeal carcinoma, Concurrent chemo-radiotherapy

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients with pathological diagnosis of nasopharyngeal carcinoma stage II ~ IVa (AJCC eighth edition) preparing to receive concurrent chemoradiotherapy

Exclusion Criteria:

  • Pregnant or lactating women
  • ECOG PS (ECOG performance status) scores of over 2 points for each day's performance assessment
  • Take anticoagulants or antiplatelet agents such as aspirin, warfarin, etc.
  • Cannot accept routine treatment, or can not cooperate with the research program

Sites / Locations

  • China Medical University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Danggui Buxue Tang group

Placebo group

Arm Description

Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.

Use Placebo 5g/time, 3 times a day, for 12 weeks.

Outcomes

Primary Outcome Measures

The correlation between next-generation sequencing analysis and traditional Chinese medicine constitution
Identification of biomarkers by next-generation sequencing analysis in nasopharyngeal cancer patients.

Secondary Outcome Measures

The quality of life as assessed by the score of questionnaire of European Organisation for Research and Treatment of Cancer C30
The quality of life for cancer patients as assessed by the score of cancer-specific questionnaire, "European Organisation for Research and Treatment of Cancer (EORTC C30)", which is cancer-specific core questionnaire for use in various cancers with 30 in Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures etc), with range from 1 (Not at all) to 4 (Very much), and from 1 (Very poor) to 7 (Excellent), scoring from 0 to 100. For functional and global quality of life scales, higher scores mean a better level of functioning. For symptom-oriented scales, a higher score means more severe symptoms.
The quality of life as assessed by the score of questionnaire of European Organisation for Research and Treatment of Cancer H&N35
The quality of life as assessed by the score of a head & neck cancer-specific questionnaire, "European Organisation for Research and Treatment of Cancer Head and Neck Module (EORTC H&N35)", with 35 items to evaluate symptoms encountered by patients with head and neck cancer in 18 domains, including in 7 multiple-item scales (Pain, Swallowing, Senses, Speech, Social eating, Social contact, and Sexuality) and 11 single items (eg, Opening mouth, Sticky saliva, Dry mouth, etc), with range from 1 (Not at all) to 4 (Very much), and from 1 (Very poor) to 7 (Excellent). EORTC H&N35)have standardized scores ranging from 0 to 100, with higher scores indicating a greater degree of symptoms.
Survival rate
Survival after treatment
Disease recurrence
Disease recurrence after treatment
Next-generation sequencing
The comparison of next-generation sequencing of human gene analysis after treatment
Immune repertoire
The comparison of IgG, IgA and T cell receptor immune repertoire after treatment
Microbiota
The comparison of gut microbiota after treatment
Tongue diagnosis
The comparison of Tongue diagnosis after treatment
Constitution in Chinese Medicine Questionnaire (CCMQ)
The Chinese medicine constitution as assessed by the score of Constitution in Chinese Medicine Questionnaire, consists of 60 items in 9 types of Chinese medicine constitution, gentleness, Qi-deficiency, Yang-deficiency, Yin-deficiency, phlegm-dampness, dampness-heat, blood-stasis, Qi-stagnation, and special diathesis, with scaling range from 1(None) to 5(Always). The score would be transform to adjusted scores as{[ (Total - the number of items)/( the number of items×4)]×100}with range from 0-100. A higher score indicates that the subject may be more likely to have the specific constitution.

Full Information

First Posted
May 16, 2018
Last Updated
July 26, 2018
Sponsor
China Medical University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03578575
Brief Title
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
Official Title
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 26, 2018 (Actual)
Primary Completion Date
July 31, 2020 (Anticipated)
Study Completion Date
July 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
China Medical University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To investigate the molecular mechanism of traditional Chinese medicine constitution, the investigators proposed a randomized, double-blind, placebo-controlled, phase II trial to recruit 120 patients with nasopharyngeal cancer. Next generation sequencing, immune repertoire, gut microbiota, traditional Chinese medicine constitution and tongue diagnosis would be examined before/after 16 weeks of treatment of Danggui Buxue Tang from the beginning of concurrent chemoradiotherapy in this project. The correlation between different examinations would be analyzed to investigate the molecular mechanism of traditional Chinese medicine constitution. Disease survival, recurrence, and quality of life would be also followed up for two years to evaluate the benefit of Danggui BuxueTang.
Detailed Description
The basis for academic excellence is the interdisciplinary cooperation. The individualized medicine is the future trends, and the theory of body constitution is the most potential study for the individualized medicine and to research the process and prognosis of disease. Technique of next-generation sequencing (NGS) is also involved to comprehend to the mechanism of the prescriptions under the theory of body constitution. The nasopharyngeal cancer is a Chinese-specific disease, and radiation therapy has remarkable effect. There are many studies proving that Traditional Chinese medication can relieve the side effect of radiation therapy. The study will combine next-generation sequencing and TCM diagnostic tool, and analyze the transformation of body constitution and the performance of genes related to radiation therapy. The results may reveal the molecular mechanism of TCM constitutions and the benefit of Danggui BuxueTang, and may be used for early screen and prevention to other cancers or diseases. Furthermore, it can help to develop the potential drugs. The study plans to collect 120 cases within two years. The participants would be divided randomly to the experimental group and control group. The blood sample would be taken for next generation sequencing analysis before the radiation therapy, and after the radiation therapy combined with traditional Chinese medication. The result of samples would be compared with each other to identify "Qi deficiency gene" and "TCM effective gene".

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasopharyngeal Carcinoma
Keywords
Nasopharyngeal carcinoma, Concurrent chemo-radiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
120 subjects are divided into experimental group and control group (placebo).
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Danggui Buxue Tang group
Arm Type
Experimental
Arm Description
Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
Use Placebo 5g/time, 3 times a day, for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Danggui Buxue Tang
Intervention Description
Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo is a very low dose Danggui Buxue Tang powder.
Primary Outcome Measure Information:
Title
The correlation between next-generation sequencing analysis and traditional Chinese medicine constitution
Description
Identification of biomarkers by next-generation sequencing analysis in nasopharyngeal cancer patients.
Time Frame
The biomarker as assessed by Next-generation sequencing analysis, Change from baseline in the gene expression at 16 weeks of treatment of Danggui Buxue Tang from the beginning of concurrent chemoradiotherapy and 2-year follow-up.
Secondary Outcome Measure Information:
Title
The quality of life as assessed by the score of questionnaire of European Organisation for Research and Treatment of Cancer C30
Description
The quality of life for cancer patients as assessed by the score of cancer-specific questionnaire, "European Organisation for Research and Treatment of Cancer (EORTC C30)", which is cancer-specific core questionnaire for use in various cancers with 30 in Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures etc), with range from 1 (Not at all) to 4 (Very much), and from 1 (Very poor) to 7 (Excellent), scoring from 0 to 100. For functional and global quality of life scales, higher scores mean a better level of functioning. For symptom-oriented scales, a higher score means more severe symptoms.
Time Frame
Change from baseline in score of questionnaire at 16 weeks of treatment of Danggui Buxue Tang from the beginning of concurrent chemoradiotherapy and 2-year follow-up.
Title
The quality of life as assessed by the score of questionnaire of European Organisation for Research and Treatment of Cancer H&N35
Description
The quality of life as assessed by the score of a head & neck cancer-specific questionnaire, "European Organisation for Research and Treatment of Cancer Head and Neck Module (EORTC H&N35)", with 35 items to evaluate symptoms encountered by patients with head and neck cancer in 18 domains, including in 7 multiple-item scales (Pain, Swallowing, Senses, Speech, Social eating, Social contact, and Sexuality) and 11 single items (eg, Opening mouth, Sticky saliva, Dry mouth, etc), with range from 1 (Not at all) to 4 (Very much), and from 1 (Very poor) to 7 (Excellent). EORTC H&N35)have standardized scores ranging from 0 to 100, with higher scores indicating a greater degree of symptoms.
Time Frame
Change from baseline in score of questionnaire at 16 weeks of treatment of Danggui Buxue Tang from the beginning of concurrent chemoradiotherapy and 2-year follow-up.
Title
Survival rate
Description
Survival after treatment
Time Frame
throughout the study, an average of 2 year
Title
Disease recurrence
Description
Disease recurrence after treatment
Time Frame
throughout the study, an average of 2 year
Title
Next-generation sequencing
Description
The comparison of next-generation sequencing of human gene analysis after treatment
Time Frame
pre-treatment and after 16 weeks of treatment
Title
Immune repertoire
Description
The comparison of IgG, IgA and T cell receptor immune repertoire after treatment
Time Frame
pre-treatment and after 16 weeks of treatment
Title
Microbiota
Description
The comparison of gut microbiota after treatment
Time Frame
pre-treatment and after 16 weeks of treatment
Title
Tongue diagnosis
Description
The comparison of Tongue diagnosis after treatment
Time Frame
pre-treatment and after 16 weeks of treatment
Title
Constitution in Chinese Medicine Questionnaire (CCMQ)
Description
The Chinese medicine constitution as assessed by the score of Constitution in Chinese Medicine Questionnaire, consists of 60 items in 9 types of Chinese medicine constitution, gentleness, Qi-deficiency, Yang-deficiency, Yin-deficiency, phlegm-dampness, dampness-heat, blood-stasis, Qi-stagnation, and special diathesis, with scaling range from 1(None) to 5(Always). The score would be transform to adjusted scores as{[ (Total - the number of items)/( the number of items×4)]×100}with range from 0-100. A higher score indicates that the subject may be more likely to have the specific constitution.
Time Frame
Change from baseline in score of questionnaire at 16 weeks of treatment of Danggui Buxue Tang from the beginning of concurrent chemoradiotherapy and 2-year follow-up.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with pathological diagnosis of nasopharyngeal carcinoma stage II ~ IVa (AJCC eighth edition) preparing to receive concurrent chemoradiotherapy Exclusion Criteria: Pregnant or lactating women ECOG PS (ECOG performance status) scores of over 2 points for each day's performance assessment Take anticoagulants or antiplatelet agents such as aspirin, warfarin, etc. Cannot accept routine treatment, or can not cooperate with the research program
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hen-Hong Chang, Ph.D.
Phone
886-4-22053366
Ext
3001
Email
tcmchh55@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, Ph.D.
Organizational Affiliation
China Medical University, China
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Han-Kuei Wu, Ph.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kun San Chao, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eric Y. Chuang, Ph.D.
Organizational Affiliation
National Taiwan University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ming-Hsui Tsai, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yu-Chuen Huang, Ph.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chia-Hao Chang, M.M.S.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yao-Ching Wang, M.M.S.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chun-Hung Hua, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Shih-Neng Yang, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ying-Chun Lin, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ti-Hao Wang, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ching Yun Hsieh, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ming-Yu Lien, M.D.
Organizational Affiliation
China Medical University, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, M.D., Ph.D.
Phone
+886-4-22053366
Ext
3501
Email
tcmchh55@gmail.com
First Name & Middle Initial & Last Name & Degree
Ching-Mao Chang, M.D.
Phone
886
First Name & Middle Initial & Last Name & Degree
Hen-Hong Chang, M.D., Ph.D.

12. IPD Sharing Statement

Learn more about this trial

To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma

We'll reach out to this number within 24 hrs